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ABSTRACT
THOMAS D. MARTZ: Precision Engineering of Micrometer and
Nanometer Droplets for Ultrasound Imaging and Therapy.
(Under the direction of Paul A. Dayton, Ph.D.)
The medical community has interest in improving techniques such as occlusion,
therapeutics and imaging through the use of liquid perfluorocarbon droplets. The abil-
ity to create a monodispersed population of liquid perfluorocarbon droplets would have
the added advantage of uniform acoustic activation parameters. A microfluidic device
with a flow-focusing orifice allowed for uniform production of perfluoropentane droplets
in the micron and submicron diameter range. These droplets are able to be stored for
over two weeks while retaining distribution characteristics. The observed activation of
the droplets shows the acoustic threshold as a function of droplet diameter with little
variability. Results showed that microfluidic technology with a pressure controlled flow
regulator will allow for greater manufacturing control of phase-change perfluorocarbons
in the micron and sub-micron size range for acoustic droplet vaporization applications.
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Chapter 1
Specific Aims
In the 1990s, the US Department of Defense supported programs that included
the creation of field-deployable microfluidic devices for detecting biological threats.
Since that time, the microfluidic process has evolved and rapidly advanced for use in
a variety of applications(Whitesides, 2006). Microfluidic devices were initially made
from glass and silicon. However, it was soon discovered that these materials did not
encompass all of the material properties that were needed for success in microfluidics.
Due to its near optical transparency and soft flexible elastomer, polydimethylsiloxane
or PDMS became the most widely used material for microfluidic applications. Also,
a notable advancement in the field, soft lithography, has made it possible to go from
design to production in less than two days(Whitesides, 2006). With the evolvement
of microfluidics, the ability to create controlled bubbles (Garstecki et al., 2004) and
droplets (Whitesides, 2006) began to develop. For example, a flow-focusing device with
a small pinch off area has been shown to create uniform droplets or microbubble samples
(Garstecki et al., 2004). The evolution of microfluidics has given us the opportunity
to create uniform droplets for applications such as contrast enhanced ultrasonography
(Kripfgans et al., 2002; Marsh et al., 2007), vessel occlusion (Kripfgans et al., 2002;
Kripfgans et al., 2005; Zhang et al., 2010), drug delivery (Rapoport et al., 2009b), or
multi-purpose systems (Fabiilli et al., 2010b). These droplets can be fabricated in the
micron and sub-micron diameter range. To the knowledge of the author, the uniform
fabrication of sub-micron droplets or sub-micron acoustic droplet vaporization (ADV)
agents, without a resulting large diameter droplet, is novel.
There are other means to create ADV vehicles such as mechanical agitation and
sonication (Fabiilli et al., 2010b; Rapoport et al., 2010). Lipids and Perfluorocarbons
(PFCs) are the most commonly used materials for ADV agents. Perfluoropentane
(PFP) was used exclusively in this research due to its boiling point (29°C) being close
to physiological temperatures. At this boiling point, the introduction of an acoustic
pressure from an ultrasound transducer, can induce a liquid to gas phase-change. An
ultrasonic induced phase change of ADV vehicles may have many different applications
including, but not limited to, controlled drug release , controlled vessel occlusion, and
an increase in contrast enhancement. Prior to our research , the fundamental problems
associated with ADV agent fabrication methods included vagueness in the activation
threshold and the uncertainty of its use in ultrasound contrast enhanced applications
based on phase-change bubble size. To address the needs of the medical ultrasonics
field, we propose the following hypothesis:
Hypothesis: The development of size-controlled micron and sub-micron droplets for
controlled vessel occlusion, drug delivery vehicles, and ultrasound contrast agents can
be created and tested using rapid prototyping microfluidic devices .
To test this hypothesis, we propose the following Specific Aims:
1.1 Aim 1: Design a versatile microfluidic device to
create a spectrum of droplet sizes with different
materials.
• Vary the diameters of channels and orifices to maximize the efficiency of the
microfluidic device. (UCI)
• Implement a notched output collection mechanism for easy collection.
1.2 Aim 2: Precisely control the input of the target
reagents into the microfluidic device.
• Implement a pressure vessel to control the input flow of the reagents for an en-
hanced and prolonged control of the sample.
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1.3 Aim 3: Create uniform/monodisperse micron and
sub-micron samples.
• Introduce a pressure control flow system to improve the control of vehicle diam-
eters.
• Demonstrate that the pressure control flow system can be used for “nano tip-
streaming” and the production of sub-micron vehicles.
1.4 Aim 4: Initiate acoustic droplet vaporization to
demonstrate controlled uniform activation and over-
all expansion.
• Create a system in which an ultrasound transducer is aligned with a microscope
objective and the sample to visually show and record ADV.
• Incrementally increase the pressure of the ultrasound transducer to reach the
ADV threshold.
• Characterize a variety of sizes and compositions to determine the droplet vapor-
ization threshold of a given diameter droplet.
1.5 Aim 5: Show that the vehicles will maintain sta-
bility over time.
• Improved the lipid formulation to reduce coalescence and thus improve the longevity
of the sample.
• Test the samples over a two week period to show that the vehicle population
stayed uniform.
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Chapter 2
Significance
2.1 Aim 1: Design a versatile microfluidic device to
create a spectrum of droplet sizes with different
materials.
“This research was a collaboration between UNC and UCI. Roger Shih and David
Bardin were the main contributors in updating device designs and microfluidic wafer
fabrication methods.”
A versatile microfluidic device created with a rapid prototyping procedure will allow
for a range of parameters to be tested cheaply and quickly. Other types of vehicle
production methods incorporate a variety of materials that may take hours to complete.
During that time, it is difficult to watch the production of the vehicles and subsequently
control the vehicle size or population. Thus, a system needed to be created that would
allow for no excess materials to be used, a real-time means of visualizing production, and
the ability to alter the vehicle population in real time. A microfluidic device allows only
the droplet materials to be introduced into the system. It is also optically transparent
for real-time production visualization and minute changes to the input system of the
device will allow for vehicle population control.
Early samples made with our microfluidic system created very delicate droplets that
could not even reach the output without coalescing. Initial designs called for the output
region of the microfluidic to have a cylinder shape in which material and droplets would
collect and wait for transfer. This was found to alter the production of the microfluidic
device over time based on how full the output cylinder was. Since this was added
variation, the system had to be changed to aid in the pressure gradient and the ease
of collection. Cutting a wedge at the end of the sample solved the pressure gradient
problem and it made collection easier. The wedge design did not hamper production
of the device and the capillary forces of the lipid and vessels on the PDMS allowed for
easy collection without having to alter the microscope setup.
2.2 Aim 2: Precisely control the input of the target
reagents into the microfluidic device.
The input process of the reagents into the microfluidic device is directly related
to the quality of the sample. Using syringe pumps, there may be a 10% variation in
the mean diameter of the output sample (Korczyk et al., 2010). The large variations
exacerbate the problems when samples are less than 20 µm in diameter. This amount
of variation makes it difficult to control the population over a long enough time frame
to produce a viable sample. Thus, a more sustainable input process is needed. It was
found that using a pressure vessel with a precision regulator substantially decreased the
amount of variation from the mean. This was a large enough improvement to create
a sample, but the added advantage was that a sample could be altered from 20µm to
5µm in a matter of seconds and remain stable.
2.3 Aim 3: Create uniform/monodisperse micron and
sub-micron samples.
Acoustic droplet vaporization is commonly shown with a polydispersed sample
(Fabiilli et al., 2010b; Rapoport et al., 2010). This creates a variance in the acous-
tic threshold based on the size of the droplet population. If the distribution is wide,
then a much higher acoustic pressure is needed to activate the population compared to
a uniform sample. Also, there is the added complexity that a large droplet that is con-
verted to a bubble with a low acoustic pressure could influence the remaining droplets’
acoustic threshold creating further uncertainty. Microfluidics were introduced into the
study in order to tailor the size distribution to a low polydispersity index. This paired
with the pressure control flow system creates uniformity in samples ranging from 800
nm to 25µm.
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2.4 Aim 4: Initiate acoustic droplet vaporization to
demonstrate controlled uniform activation and over-
all expansion.
PFP droplets have been shown to be slightly echogenic (Kripfgans et al., 2002;
Marsh et al., 2007) but a PFP gas bubble has shown to be highly echogenic within a
given system. The samples would not be useful unless they were susceptible to ADV.
The samples created were able to be converted to a bubble with a size-dependent
acoustic pressure. After droplets were activated via vaporization, the echogenicity of
the resulting bubbles would allow for applications such as perfusion mapping. Droplet
vaporization also makes drug delivery possible as this allows the drug to be housed
within the droplet shell protected from its surroundings or coated and attached to the
outside of the shell. Upon activation, the drug would be released at site-specific targets
to reduce systemic toxicity. Embolotherapy is also possible as the theoretic expansion
rate of the droplet is approximately 6 times the initial diameter. Reducing the blood
flow of a site-specific area to a high degree could lead to ischemic necrosis (Kripfgans
et al., 2005). There have also been cases where occlusion is paired with drug delivery
in the effort to increase the residence time of the chemotherapeutic in the target area.
2.5 Aim 5: Show that the vehicles will maintain sta-
bility over time.
Initial droplets were unable to be transferred from the microfluidic device to a
storage container. This would make the samples unusable for any type of scale-up
applications. The formulation of the lipid composition was allowing the droplets to
coalesce or burst. This caused the lipid reagent to be reformulated twice in order to
achieve a droplet population that has the ability to last for at least two weeks. The
idea behind keeping the samples refrigerated for two weeks was so that these samples
could be made in a laboratory, shipped to the user, and sit until final use. During this
time frame, the droplet population should maintain a similar distribution for continuity.
Overall, the sample has to last long enough to use it and the reformulated lipid reagent
allows for easy handling, use and longevity of the vehicles.
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Chapter 3
Innovation
3.1 Aim 1. Design a versatile microfluidic device to
create a spectrum of droplet sizes with different
materials.
“This research was a collaboration between UNC and UCI. Roger Shih and David
Bardin were the main contributors in updating device designs and microfluidic wafer
fabrication methods.”
With the creation of the initial microfluidic device, it became possible to go from
design to use in less than two days (Whitesides, 2006). Also, with the addition of the
flow focusing device, two or more materials could be introduced into a flow-focusing
device to create a variety of samples including multi-layer vehicles (Hettiarachchi et al.,
2009), ADV agents (Martz et al., 2011; Sheeran, 2011; Sheeran et al., 2011b; Sheeran
et al., 2011a), and Janus particles (Malloggi et al., 2010). The innovation of the mi-
crofluidic device is in the ability to pattern a 6 micron-orifice to allow for balance in
production between sub-micron sizes and micron sizes. Another improvement is the
addition of a complex filtering system, which stops the device from clogging. In normal
circumstances, the fabrication technique can produce objects that are larger than 6
microns, which halted production of droplets. The filtering system evolved over the
duration of this research to allow for upwards of 60 psi to be placed on the reagents to
induce flow without the fear of clogging.
In relation to sample collection, an initial problem was the large bulk output hole.
This large hole created a pressure gradient over time depending on the amount of
droplets and excess lipid at any given time. This pressure gradient created instabilities
in the production of the droplets leading to samples with a nonuniform distribution.
In an attempt to stabilize production, Tygon tubing was placed into the output hole
to allow the material to flow into a collection vessel. Unfortunately, droplets sink in
a lipid medium and in our method, the droplets were required to go up a slight slope
before they could be collected in the vessel. Therefore, the droplets had to build up
before moving into the collection vessel, which ultimately led to the previously described
pressure gradient. The innovation came with the introduction of a “V” shaped slice in
the output of the device where capillary forces act at the PDMS and glass interface to
allow for easy collection of the droplets with minor lipid waste.
3.2 Aim 2. Precisely control the input of the target
reagents into the microfluidic device.
Initially, to create multi-layered acoustically active liposomes, four syringe pumps
were used for the introduction of reagents. ADV agent research required just two
materials, thus we were able to reduce the overall number of syringe pumps to two.
Syringe pumps were used as a controllable method for the introduction of the reagents
into the microfluidic device due to their ability to maintain hysteresis over a duration
of time when the flow rate was changed. However, there was play between the syringe
pump and the syringe holding the reagent, the use of a plastic syringe induced flexibility
to the chamber complicating the fluidity of the reagent flow, and the syringe pumps
did not allow for precise control of the reagent flow that is required to create uniform
ADV agents. These issues led to the initiation of a new method for introducing the
reagents.
The innovation in this research was the use of a pressure control flow system to
introduce the reagents into the microfluidic device. A constant and instantly updatable
pressure head was placed on the top of the reagent in a pressure vessel. A line submerged
in the reagent equalized the pressure by sending the reagent to the microfluidic device
initiating flow. Although not personally studied, the initial knowledge for this design
showed that there was less than 1% variation of the mean diameter of droplets overtime
(Korczyk et al., 2010). This advancement allowed for more uniform droplet production
and diameter variation from sub-micron droplets to micron droplets in a matter of
seconds.
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3.3 Aim 3: Create uniform/monodisperse micron and
sub-micron samples.
Initial microfluidic designs utilized an orifice larger than 10 microns. This prevented
many of the smaller size samples from being produced due to geometric constraints and
the inability to control the flow of the reagents precisely. The innovation of a smaller
orifice (6 microns patterned), along with the ability to precisely control the flow of
reagents with a pressure vessel, has allowed the effortless production of monodisperse
micron sized droplets and the uniform production of sub-micron droplets.
Droplets were created with the use of syringe pumps during the initial studies of
this research. This required 100% focus on the device screen to ensure that the droplets
did not vary and the uniformity of the sample was not compromised. The innovation
of the pressure control flow system to create the uniform samples was the breakthrough
that was needed for stable sample creation. With the new pressure control flow system,
there is an instant update of droplet size based on the input pressures, the ability to
perform nano tip-streaming to produce sub-micron droplets, and the ability to leave
the system for hours to produce bulk samples without the fear of variation from the
initial droplet diameter. According to a recent literature search, this microfluidic device
is the first to create sub-micron droplets with the capability to achieve ∼300nm.
3.4 Aim 4: Initiate acoustic droplet vaporization to
demonstrate controlled activation and overall ex-
pansion.
Initially, the fabricated droplets coalesced over time. Thus, it would take less pres-
sure to activate the droplets, thereby disrupting the actual activation threshold of the
correct size droplets. This was also compounded with the initial problems of droplet
collection, which resulted in an increase in droplet coalescence and a wider distribu-
tion of droplet diameters. The innovation was a joint effort between an improved lipid
formulation, pressure control flow system, and “V” collection method. These allowed
for uniform sub-micron and micron droplets to be produced consistently over time to
produce a viable sample without coalescence of resulting droplets, and thus providing
an easy collection for implementation into the ultrasound testing apparatus.
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3.5 Aim 5: Show that the vehicles will maintain sta-
bility over time.
Initial droplets were produced with a pure lipid solution that allowed droplets to
coalesce into sizes outside the spectrum of the research before they could even be
collected. The lipid solution was reformulated adding surfactant and glycerol, which
prevented the droplets from coalescing over time and from the weight of other droplets.
With the innovation of an equal ratio of lipid to surfactant to glycerol, coalescence
was avoided and allowed the samples diameter distribution to stay relevant over an
industrially applicable time.
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Chapter 4
Materials & Methods
4.1 Materials Database
Table 4.1: Materials Used During Research
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4.2 Microfluidic Device Fabrication
“This research was a collaboration between UNC and UCI. Roger Shih and David
Bardin were the main contributors in updating device designs and microfluidic wafer
fabrication methods.”
Initial flow-focusing channel designs were created in Adobe Illustrator. The basic
layout of the design is pictured in figure 4.1. There are two input holes located on the
device with one larger output hole. The design strategy surrounding the flow focusing
device is that the outside input hole (lipid) branches to a “T” as illustrated. This
“T” branching is brought around the second input hole (PFP) to create a sandwich
of lipid/PFP/lipid. This sandwich is located at the flow-focusing region in a pinched
orifice that was patterned to be approximately 6 µm. After the orifice, there is an arrow
shaped output channel that leads to the output orifice.
The design in Adobe Illustrator was printed at 20,000 dpi by CAD/Art Service and
subsequently used as the mask for the silicon wafer. This silicon wafer was first oxidized
with the use of a plasma cleaner and spin-coated with a UV curable photoresist. The
printed mask was then aligned to the wafer using alignment markers.The wafer was
exposed to UV light to develop the channel patterns for use as a negative for device
production. The negatively patterned device was then secured in a Petri dish.
Polydimethylsiloxane (PDMS) and a curing agent were placed into a measuring cup
in a 10:1 ratio. These materials were mixed resulting in a thick solution containing
many small bubbles. The entire contents were then poured over the silicon wafer in the
Petri dish. The thickness of the device was a minimum of 1 cm. The Petri dish was then
transferred to a vacuum for at least 3 hours to remove any bubbles. A light nitrogen
blast helped to remove any residual bubbles that remained in the device area. Lastly,
the Petri dish was placed in an oven at 60°C for a minimum of 5 hours to complete the
PDMS curing process.
The remaining steps for microfluidic device production were performed in a laminar
flow hood. To assist in the removal process, the devices were cut from the PDMS when
the PDMS was still warm from the oven. A syringe was used to create a circular cut in
the PDMS just inside the outside diameter of the silicon wafer. The circular piece of
PDMS was then removed and a razor blade was then used to separate the individual
devices.
Individual devices remained inverted in the hood at all times to avoid dust or
contaminants. A blunt tip needle was used to remove the PDMS located over the two
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input hole regions approximately the size of the Tygon tubing. A razor blade was then
used to cut a triangle shape that extends off the device at the output location. The
surface and holes were cleaned out with ethyl alcohol and dried with a nitrogen gun.
Then, a glass slide was cleaned with ethyl alcohol dried with a nitrogen gun. Care was
taken to ensure that there was no residue or debris on the glass slide, which would
potentially lead to device failure. The microfluidic channels and glass slide were then
placed in a plasma cleaner on high at 500 millitorr for 3 minutes. The microfluidic
channels and glass were immediately joined together and held together for at least 30
seconds to ensure a secure bond. Finally, the device channels were filled with DI water
and sealed with a piece of scotch tape.
Figure 4.1: Microfluidic Device Layout
4.3 Reagent Preparation
PFP was kept sealed after transfer to ensure the PFP did not evaporate. Initial lipid
was created using chloroform to dissolve a 9:1 molar ratio of 1,2-distearoyl-snglycero-3-
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phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy-
(polyethylene glycol)-2000] (DSPE-PEG2000). The chloroform was subsequently evap-
orated with the use of a nitrogen gun. For the two lipid compositions used in this
research, DI water was added as the base for the lipid solutions. The first lipid com-
position included the addition of 50 mL of DI water and was sonicated for 20 minutes.
After this, 47 mL of DI water was added along with 2 mL of glycerol, 1 mL of propy-
lene glycol, and 10 mL of pluronic F-68 surfactant. Finally, this was vortex mixed for
1 minute and sonicated for 10 minutes. This was then used as the lipid reagent for
droplet production. The second lipid composition was created with the base ratio as
previously stated. 1 mL of the lipid composition was added to 1 mL of glycerol, and
1 mL of pluronic F-68. This solution was then lightly vortex mixed until the appear-
ance of a homogeneous solution. This was then used as the lipid reagent for droplet
production.
4.4 Reagent Flow Control
Initial studies were performed with the use of two syringe pumps. These pumps
were placed on stages to ensure that the syringe height was located at the height of the
microfluidic device. A 5 mL syringe was used as the lipid container and the PFP was
housed in a 3 mL syringe. The syringes had a needle at the output that was connected
to Tygon tubing, which ran to the microfluidic device inputs. Pressure vessels were
used for the remainder of the research due to our need to precisely control the fluid
flow. 3 mL of PFP were placed in a 3 mL serum vial. This vial was then capped. Also,
3 mL of lipid reagent was placed in a 3 mL serum vial. This vial was also capped. The
septa that were used to cap the vials had two holes placed in them that were slightly
smaller than that of the Tygon tubing. A strand of Tygon tubing was placed in each
hole. One strand in the headspace of the vial went to a precision pressure controller.
This pressure controller was also connected to a pressure gauge as well as an output
hole. This output hole contained rigid tubing that ran to a Nitrogen tank. The Tygon
tubing submerged in the given reagent went directly to the input hole of the microfluidic
device. The two reagents were then able to be precisely pressure controlled to receive
the desired flow rates thus producing the desired droplets.
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Figure 4.2: Syringe Pump System and the Pressure Control Flow System
4.5 Microfluidic Droplet Production
The microfluidic devices were placed into a custom made holder on the top of a 2D
adjustable stage on an inverted microscope. The microfluidic device was then brought
into focus with a 50x objective. A high-speed camera was connected to the microscope
for video recording purposes. The amount of light was adjusted to create the proper
brightness for video collection. A variety of different frame speeds and shutter speeds
were used to record droplet production videos.
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Figure 4.3: Microfluidic Device Testing Setup
4.6 Sample Collection
Droplets emerged from the output triangle along with excess lipid. A 1 mL pipetter
set at 250 µm was placed at the edge of the PDMS and glass. The droplets and excess
lipid were then captured and pipetted into a 3 mL serum vial. On completion of the
sample collection, the vial was capped and placed in a refrigerator at 4°C.
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Figure 4.4: Microfluidic Droplet Collection Methods
4.7 Acoustic Droplet Vaporization
A heated water bath was placed on an inverted microscope with a 100x water
immersion objective. A hydrophone was placed in the focused region of the microscope
until the tip was visible. A transducer was submerged in the water bath and focused to
the hydrophone which was also in the focus of the microscope. Then, the hydrophone
was removed and a cellulose testing tube was placed in the optical focus. A cellulose
testing tube was made with a brass “U” shaped rod, Tygon tubing, and a small amount
of cellulose tubing. Tygon tubing was hot glued to one side of the brass rod. A piece
of cellulose tubing was then glued into the Tygon tubing. The cellulose tube was then
hydrated and another piece of Tygon tubing was glued to the cellulose tubing. The
piece of Tygon tubing was then glued to the other side of the brass rod creating a tight
area of cellulose tubing in the “U” of the brass rod.
The sample was then precisely input into the tube to focus on individual or groups
of droplets. The input pulse was a single cycle, which was ramped up in pressure until
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the droplet was activated to a gas bubble. Video was taken before and after activation
with the use of a high-speed camera.
Figure 4.5: Acoustic Droplet Vaporization Testing Setup
4.8 Sample Processing
Image J was used to analyze the diameter of the droplets produced in the mi-
crofluidic device and the droplets before activation. A microscope reticle was used for
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distance calibration of the video images. Production rates were determined by count-
ing the amount of droplets that passed a given distance on the video in a set time
provided by the high-speed camera. Populations of data were imported into Excel for
data processing.
Sub-micron bulk samples were analyzed using a Malvern Nano ZS. This allowed
determination of the mean and the standard deviation of the droplet populations. An
aliquot of sample was pipetted into a a cuvette along with 0.5 mL of phosphate buffered
saline. To image the sub-micron droplets a negative staining TEM procedure was used.
Samples were applied to a grid, stained with 1 % uranyl acetate and then imaged in
the TEM.
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Chapter 5
Results
5.1 Aim 1: Design a versatile microfluidic device to
create a spectrum of droplet sizes with different
materials.
“This research was a collaboration between UNC and UCI. Roger Shih and David
Bardin were the main contributors in updating device designs and microfluidic wafer
fabrication methods.”
The microfluidic device that was used in this experiment was modeled from a previ-
ous study. This initial design contained no filtering and contained a large 20 µm orifice.
Design iterations on this initial design yielded a much smaller orifice to create smaller
samples. The first design contained diagonal slits to filter unwanted material from mov-
ing downstream to the orifice that was approximately 10 µm in width. From this, initial
droplets were able to be created and vaporized, but they were not in the desired size
range for medical ultrasonics (< 7 µm). In order to get the droplets smaller, the design
was changed to include a triangular shaped obstacle pattern for enhanced filtering and
the orifice was decreased to approximately 6 µm. This design yielded droplets in the
size range required, <7 µm. Furthermore, the filtering system along with the pressure
control flow system, allowed for the production of sub-micron droplets.
Figure 5.1: Microfluidic Device Filter System
A difficulty in collecting the droplet sample was having to move the light source
away from the microfluidic device in order to remove the sample. Also, upon placing the
sample in a collection vial, numerous droplets were vaporized due to pressure changes
when they were output from the pipette. When the light source was away from the
microfluidic device, it was not possible to watch the sample being created and on
numerous occasions the droplet diameter changed by the time the light source was
placed back on the microfluidic device. The fluctuation of fluid in the microfluidic
device output also caused fluctuations as this attributed to the difference in droplet
diameter when the light source was placed back on the microfluidic device. The first
attempt to fix this was to place a piece of Tygon tubing in the output straight to
the collection vessel. This appeared to fix the pressure gradient that was based on
the amount of fluid in the output orifice but created a height differential that the
droplets had to scale before they could be placed in the collection vessel. In an attempt
to circumvent this problem, a wedge design was cut into the exit orifice for sample
collection, which allowed easy access for the pipette to collect the sample as the light
source remained on the device. The pressure gradient at the output was also stabilized
as there was freedom for the output fluid and droplets to escape the device. Surface
chemistry also played a role causing the output fluid and droplets to nest in at the
boundary between the PDMS and glass.
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Figure 5.2: “V” Shape Collection System
5.2 Aim 2: Precisely control the input of the target
reagents into the microfluidic device.
Initially, two syringe pumps were used. Unfortunately, this particular setup made it
difficult to simultaneously control two syringe pumps, especially with the low viscosity
PFP in a horizontal syringe. Initial thoughts by the author were that the syringe pumps
maintained a lot of give in relation to the plastic syringe holding the reagent and that
the system would not stay stable even after an adequate soak time. This created
samples with a lot of size variation. Korczyk et al.(Korczyk et al., 2010) showed that
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there was a large amount of variation with syringe pumps and offered a simple low
cost alternative. The basic design used a pressure vessel with an input and output.
This design was used as the basis for the pressure control flow system shown here.
The pressure control flow system ensured that only small amounts of material needed
to be used, allowed for effortless control of reagent flow, and the eventual creation of
sub-micron droplets.
Figure 5.3: Consistent Monodispersed Droplet Production
5.3 Aim 3: Create uniform/monodisperse micron and
sub-micron samples.
Numerous systems have to be in harmony to allow uniform/monodispersed micron
samples to be created, not to mention sub-micron droplets. The microfluidic device has
to be free of debris, sealed to the glass slide to ensure there are no breaks in geometry
and resist flexing at higher pressures. The reagents have to be homogeneous, prevent
coalescence once the droplets are created and have the ability to be collected. The
pressure control flow system has to have a consistent amount of pressure applied to the
reagents to ensure reliable flow rates and be easily controlled to alter droplet diameter.
To allow uniform/monodispersed micron and sub-micron droplets, the microfluidic de-
vice went through two iterations, the lipid formulation was altered twice and pressure
control flow system needed to be created.
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Figure 5.4: Initial Coalescence
Figure 5.5: Initial Population Distributions
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Figure 5.6: Uniform Sub-micron Droplet Production
5.4 Aim 4: Initiate acoustic droplet vaporization to
demonstrate controlled activation and overall ex-
pansion.
Initial droplets created with the microfluidic system could not be removed from the
microfluidic device to be placed in the acoustic testing apparatus. Iterations of the lipid
composition were changed as well as the collection strategy that allowed the droplets
to be administered into the acoustic testing apparatus. This then allowed a 5 MHz
and 3.5 MHz transducer to administer a pressure pulse. Numerous droplet diameters
were tested to determine that there is a discrete acoustic threshold for each diameter
faction. Also, the activation threshold followed a logarithmic trend that shows the
acoustic threshold increases as diameter decreased.
26
Figure 5.7: Acoustic Droplet Vaporization
5.5 Aim 5: Show that the vehicles will maintain sta-
bility over time.
To reiterate, the initial droplets created during this study were unable to be removed
from the microfluidic device, which meant that they were not stable enough to last for
an applicable time frame. This caused two iterations of lipid compositions to be created
and a wedge collection style to be implemented. This allowed samples to be tested at
incremental times through the span of two weeks. The results showed that the droplet
diameters maintained a similar size and distribution compared to the day they were
created. This then correlated to the droplets lasting an industrially applicable time
frame similar to creation, shipping, storage, and medical use.
Figure 5.8: Stability of Droplets over 2 Weeks
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Chapter 6
Results
The work presented here shows how improvement in different areas of the project
culminated in the advancement of the ADV agent field. Microfluidic changes, reagent
optimization, flow delivery mechanism and collection protocol all played a major role
in the overall success of the project.
Microfluidics have allowed for the creation of monodispersed ADV agents. The
initial microfluidic device was overhauled to allow for a smaller orifice and superior
debris filters. The advancement in the microfluidic design allowed for progressively
smaller droplets. Initial droplets were created with a diameter that was approximately
20 µm. The finalized design, on the other hand, produced droplet diameters that were
∼7 µm.
The reagent optimization was directly related to the overall population variation
and the ability to collect the sample. Initial samples, regardless of creation diameter,
would coalesce in the output of the microfluidic device resulting in a higher standard
deviation. After creation of the final lipid composition, there was a drastic decrease in
coalescence that improved the standard deviations of the output samples.In addition, it
allowed for smaller droplet creation and easier collection. Syringe pumps have become
common place when it comes to introducing reagents into a microfluidic device. In many
cases, the ability to precisely control the flow over time is not necessary. However, in
the application of fabricating monodispersed ADV agents, precise control is a necessity.
Syringe pumps were used initially in this study, but it became evident early on
that they were not precise enough to maintain a constant diameter. Many days were
spent using coarse pressure adjustments to compensate for lack of precision. This led
to the creation of a pressure control flow system. The system had the ability to accu-
rately control the production diameter of the sample and maintain that diameter over
a necessary amount of time for sample collection. The pressure control flow system also
allowed for the introduction of the term “nano tip-streaming”. This type of microfluidic
droplet production enabled sub-micron droplets to be created.
Finally, the sample had to be collected and transported to be viable for any ap-
plication. The initial collection mechanism caused a pressure gradient at the output
and depending upon the amount of material in the output orifice, the diameter would
vary. This variation in the sample would cause the standard deviation to be too high
rendering the sample unusable. The need for an output with a minimized pressure
gradient was sought after and it was found that a wedge cut at the orifice of the device
allowed for easier collection and did not alter the production of the sample based on
the amount of material at the output.
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Chapter 7
Conclusion
A microfluidic flow focusing device was able to create uniform sub-micron and
micron-sized ADV agents. These agents were susceptible to ultrasound pressure for
applications such as vessel occlusion, controlled drug delivery, and contrast enhance-
ment. A pressure control flow system allowed for effortless tuning of droplet diameter
and allowed for the first ever sub-micron ADV droplet creation with the use of mi-
crofluidics.
Chapter 8
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8.1 Precision Manufacture of Phase-Change Perfluo-
rocarbon Droplets using Microfluidics 1
Thomas D. Martz1, Paul S. Sheeran2, David Bardin3, Abraham P. Lee3, and Paul A.
Dayton2,∗
1Curriculum of Applied Sciences and Engineering - Materials Science, The Univer-
sity of North Carolina, Chapel Hill, NC, 27599
2Joint Department of Biomedical Engineering, The University of North Carolina
and North Carolina State University, Chapel Hill, NC, 27599
3Department of Biomedical Engineering, The University of California at Irvine,
Irvine, CA, 92697
8.1.1 Abstract
Liquid perfluorocarbon droplets have been of interest in the medical acoustics com-
munity for use as acoustically activated particles for tissue occlusion, imaging, and
therapeutics. To date, methods to produce liquid perfluorocarbon droplets typically
result in a polydisperse size distribution. Because the threshold of acoustic activation is
a function of diameter, there would be benefit from a monodisperse population to pre-
serve uniformity in acoustic activation parameters. Through the use of a microfluidic
device with flow-focusing technology, the production of droplets of perfluoropentane
with a uniform size distribution is demonstrated. Stability studies indicate that these
droplets are stable in storage for at least two weeks. Acoustic studies illustrate the
thresholds of vaporization as a function of droplet diameter, and a logarithmic rela-
tionship is observed between acoustic pressure and vaporization threshold within the
size ranges studied. Droplets of uniform size have very little variability in acoustic va-
porization threshold. Results indicate that microfluidic technology can enable greater
manufacturing control of phase-change perfluorocarbons for acoustic droplet vaporiza-
tion applications.
Keywords: Acoustic droplet vaporization, Ultrasound, Monodisperse, Perfluoropen-
tane, Microfluidic
1 c○ Elsevier. Reprinted, with permission, from T. D. Martz, P. S. Sheeran, D. Bardin et al.,
“Precision Manufacture of Perfluorocarbon Droplets for Acoustic Droplet Vaporization,” Ultrasound
in Medicine and Biology, 2011.
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8.1.2 Introduction
Acoustic Droplet Vaporization Agents
In acoustic droplet vaporization (ADV), acoustic pressure delivered to a liquid
droplet by an ultrasound (US) transducer provides the additional energy necessary
to induce a liquid-to-gas phase transition. This phase transition allows for unique ap-
plications that are not possible with standard microbubble contrast agents, because
ADV agents exhibit a very large volume change after activation. In addition, ADV
agents are typically poorly echogenic in their liquid form, but highly echogenic as gas
bubbles.
The basic construction of an ADV agent consists of a volatile liquid core that can be
converted to a gas with additional energy. Typically, ADV droplets consist of perfluo-
rocarbons (PFC) such as perfluoropentane (PFP) (Zhang et al., 2010), perfluorohexane
(PFH) (Giesecke and Hynynen, 2003; Fabiilli et al., 2010b), or perfluorooctane (Fabiilli
et al., 2009). The most commonly used PFCs, PFP and PFH, have boiling points near
physiological temperatures (29°C and 56°C, respectively). Recently, stabilization and
ADV capability of droplets of liquid perfluorobutane (boiling point of -1.7°C) has been
demonstrated (Sheeran et al., 2011a).
Producing (PFC) droplets in the micron and sub-micron range increases the Laplace
pressure exerted on the liquid core, enabling small droplets to be maintained in liquid
form even above their vaporization temperature. The addition of a stabilizing shell
reduces droplet coalescence and increases stability of the emulsions (Kripfgans et al.,
2005; Rapoport et al., 2009b; Sheeran et al., 2011a). Commonly utilized methods of
producing PFC droplets include sonication or high-speed mechanical agitation of the
host solution, which typically results in a polydisperse population (Fabiilli et al., 2010b;
Rapoport et al., 2010).
Acoustic Droplet Vaporization Applications
Liquid perfluorocarbon droplets have been shown to provide ultrasound image con-
trast (Kripfgans et al., 2002; Marsh et al., 2007), although the backscatter is notably
less than similarly sized microbubble agents. One of the first commercial applications
of perfluorocarbon droplets for US contrast enhancement was Echogen (Sonus Phar-
maceuticals, Bothell, WA, USA), a perfluoropentane emulsion (Quay, 1998). Clinical
trials for Echogen were abandoned in 2000 before FDA approval could be obtained.
Once vaporized, ADV agents are readily detectable by an imaging system even at
low concentrations. In very small amounts, droplets when converted to bubbles through
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ADV could act as point beacons for phase aberration corrections (Apfel, 1998; Haworth
et al., 2008). The unique advantages of ADV droplets in the 100-nm size range is that
they have the potential to extravasate from the vasculature and into the tissue, enabling
ADV-based contrast imaging or therapy to extend beyond the vascular space, where
traditional microbubbles cannot access (Rapoport et al., 2007; Rapoport et al., 2009a;
Sheeran et al., 2011a).
One of the most well studied applications of ADV is embolotherapy. This tech-
nique enables the intentional creation of an occlusion in a specific tissue to limit blood
flow. This has been proposed to treat renal cell carcinoma, to reduce blood loss for
hypervascular tumors, and to treat hemorrhaging (Kripfgans et al., 2002; Zhang et al.,
2010). Kripfgans et al. (2005) (Kripfgans et al., 2005) demonstrated that a filtered
emulsion of droplets, which is intra-arterially injected, can reduce kidney perfusion by
70 %. This level of organ perfusion reduction has the ability to cause ischemic necro-
sis for therapeutic applications, or it can enhance the utility of radiofrequency tissue
ablation by minimizing thermally dissipative effects due to reduced flow (Kripfgans
et al., 2005). A second application of ADV agents is site-specific therapeutics, where
the goal is to deliver a potent agent only to the disease site while minimizing systemic
effects. The ADV-mediated delivery of a chemotherapeutic drug directly to the tumor
has been shown to mediate regression of ovarian and breast cancer (Rapoport et al.,
2009b). ADV agents that have the ability to carry a therapeutic payload to a desired
vessel could be combined with vessel occlusion upon activation to allow for an increase
in residence time of the therapeutic agent (Fabiilli et al., 2010b).
With spatial and temporal control over ADV agent activation, ADV agents can be
used as a nucleation site for high-intensity focused ultrasound (HIFU) tumor ablation.
During HIFU, the microdroplets can be activated to increase the therapeutic effect or
decrease the treatment time (Zhang and Porter, 2010; Zhang et al., 2011).
Considerations of ADV agent size distribution
The size of ADV agents is an important factor in determining the vaporization
threshold and the biodistribution. The Antoine equation predicts a negative logarith-
mic relation between droplet size and activation energy, where larger droplets require
less energy to vaporize than smaller droplets (Rapoport et al., 2009a). Most who have
characterized ADV-based agents have evaluated a polydisperse droplet population. Al-
though general trends in thresholds have been observed, polydispersity in droplet sizes
has led to a variability in the vaporization threshold measured for studies that ex-
amine a bulk population of ADV droplets. In addition, the larger droplets vaporize
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at lower energies and the resulting bubbles can influence the threshold energy for the
smaller droplets (Lo et al., 2007), confounding in-vitro characterization of vaporization
thresholds. Because microbubbles combined with high acoustic pressures can lead to
unwanted bioeffects (Miller et al., 2008), it may be desirable to perform ADV at the
minimum acoustic pressure required. A polydisperse sample may require a higher pres-
sure to efficiently vaporize the entire population due to smaller droplets requiring more
energy.
For micron-sized ADV agents, one of the primary applications is vessel occlusion,
where it may be important to have a well-characterized distribution of droplet sizes to
target a specific vascular diameter while not affecting other vessels (Kripfgans et al.,
2005). For the same reasons, a droplet designed for imaging applications that is too
large could lodge in the lungs or other organs after IV injection, leading to undesired
vessel occlusion. All of these limitations are motivating reasons for precise size control
of ADV agents.
Previous studies to improve the size distribution characteristics of perfluorocarbon
droplets have involved microfluidic sorting (Huh et al., 2007) and filtering (Kripfgans
et al., 2005). The microfluidics platform is well known for the ability to create particles,
droplets (Tan et al., 2004; Xu et al., 2006; Teh et al., 2008), microbubbles (Hettiarachchi
et al., 2007a), and multi-layer particles (Hettiarachchi et al., 2009) of uniform size. In
this manuscript, we assess the feasibility for producing a monodispersed ADV agent
through a microfluidic technique to achieve uniform activation thresholds.
8.1.3 Materials and Methods
Reagent Preparation
Lipid PFP was purchased from FluoroMed, L.P. (Round Rock, Texas, USA). Lipid
solutions were created using a 9:1 molar ratio of 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC) (Avanti Polar Lipids, Alabaster, AL, USA) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N[methoxy-(polyethylene glycol)-2000] (DSPE-PEG2000) (Avanti
Polar Lipids) in a 110-mL solution of deionized (DI) water, glycerol (Fisher Scientific,
Pittsburgh, PA, USA), propylene glycol (Fisher Scientific, Pittsburgh, PA, USA), and
pluronic F-68 (Sigma-Aldrich Corporation , St. Louis, MO, USA).
Fifty mg of DPSC and 19.6 mg DSPE-PEG2000 were dissolved in chloroform. The
chloroform was then evaporated with N2, after which 50 mL of DI water was added
and the resulting solution was sonicated for 20 minutes. After sonication, 47 mL DI
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water, 2 mL glycerol, 1 mL propylene glycol, and 10 mL pluronic F-68 were added.
The solution was vortex mixed for 1 minute and then sonicated for 10 minutes.
Microfluidic Device Fabrication
The process for developing the microfluidic wafer has been previously described
by Hettiarachchi el al. (2009) (Hettiarachchi et al., 2009). Briefly, the channels were
created using Illustrator (Adobe, San Jose, CA, USA) and printed (20,000 dpi) by
CAD/Art Services (Brandon, OR, USA). In a clean room, the wafer was first oxidized
in oxygen plasma and then spin-coated with a UV curable epoxy (SU-8-25, MicroChem,
Newton, MA, USA). On exposing the wafer to UV light, the channel patterns develop
to use as a negative for device production.
With the wafer in a petri dish, Polydimethylsiloxane (PDMS) (Dow Corning, Mid-
land, MI, USA) and a curing agent were poured over the wafer at a 10:1 ratio, respec-
tively. This was then placed under vacuum for 24 h and then cured at 60°C overnight.
After the PDMS was cured, the individual microfluidic devices were removed from the
wafer. The individual microfluidic device and a clean microscope slide (2947-75X25,
Corning, Corning, NY, USA) were placed in a plasma cleaner (Harrick Plasma, Ithaca,
NY, USA) and exposed to a plasma field under a controlled pressure of 500 mTorr
for 3 minutes. Upon completion of the plasma cleaning process, the PDMS and glass
slide were immediately joined, forming complete microchannels. One minute after the
bond was established, DI water was injected into the channels to create a hydrophilic
environment.
Microfluidic Experimental Apparatus
The microfluidic experimental apparatus was set up similar to that as described
previously by Kaya et al. (2010)(Kaya et al., 2010). Briefly, the microfluidic device
was secured to a moving stand on an inverted microscope (Olympus 1X71 microscope,
Center Valley, PA, USA), and viewed with a 50X NA = 0.5 objective. A high speed
camera (Fastcam APX-RS, Photron, Inc., San Diego, CA, USA) was used to capture
images and videos of the device output. Reagents were injected from syringes into device
channels through Tygon S-54-HL tubing (Saint-Gobain Performance Plastics, Akron,
OH, USA). Calibrated syringe pumps (Harvard Apparatus, Holliston, MA, USA) were
used to control rate of material flow in individual microchannels.
Sample Production
To produce uniform samples, the PFP flow rate was fixed at a constant value and
the lipid flow rate was increased until the smallest stable droplets were formed. The
system was allowed to stabilize for 5 minutes before collection, because pressure changes
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in the system required a few minutes to equalize. This process was repeated across a
range of different flow rates, as described in Table 8.1. To determine the production
rate for the microfluidic device, high-speed video analysis of the droplet production was
performed. Time stamps enabled the determination of droplet production rate.
Acoustic Experimental Apparatus
The experimental setup to determine droplet vaporization thresholds was similar
to that previously described by Sheeran et al. (2011)(Sheeran et al., 2011a). Briefly,
a heated water bath maintained at 37°C was connected to an inverted microscope.
Droplets were injected through a nearly acoustically and optically transparent mi-
crocellulose capillary tube with an inner diameter of 200 µm (Spectrum Labs, Inc.,
Greensboro, NC, UNC). A 5-MHz piston transducer (IL0506HP, Valpey Fisher Corp.,
Hopkinton, MA, USA) was positioned in the water bath confocally with a water immer-
sion microscope objective (100x, NA=1.0). The output of the ultrasound transducer
was calibrated by inserting a needle-hydrophone (HNA-0400, Onda Corp., Sunnyvale,
CA, USA) into the experimental system at the exact location where the samples are
positioned during activation studies (the focus of the microscope objective). Droplets
were exposed to single 10-cycle sinusoidal pulses while the ultrasound pressure was
increased incrementally until droplet vaporization was observed. The procedure was
repeated for at least 20 droplets from each size distribution to verify droplet size and
threshold.
Stability Analysis
Droplets were stored at 4°C in 3-mL vials until sampling. For analysis, a 25-
µliter aliquot of droplets was placed on a glass slide, and images were captured with
the Photron Fastcam camera. Size measurements were performed in ImageJ (NIH,
Bethesda, MD, USA) by comparison to a calibrated reticle (Edmund Industrial Optics,
Barrington, NJ, USA). A minimum of 50 droplets was measured for each population.
8.1.4 Results
The dimensions of the microfluidic device, material composition, and flow rates all
have the ability to alter the composition of the resulting droplet. Due to the micro-
fabrication process, there are minute variations from device to device (we measured a
13% deviation in orifice widths across 10 devices). With this in mind, only one device
was used for the duration of production to ensure that the dimensions of the device
were unchanged. The material compositions also went unchanged to ensure that the
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Figure 8.1: High-speed video frames of microfluidic droplet production at diameters of
(a) 20.4±0.3 µm, (b) 16.2±0.5 µm, (c) 12.6±0.5 µm, (d) 10.3±0.4 µm and (e) 7.4±0.4
µm, corresponding to lipid and PFP flow rates of lipid 40 µL/min; PFP 12.5 µL/min,
lipid 31 µL/min; PFP 15 µL/min, lipid 40 µL/min; PFP 15 µL/min, lipid 50 µL/min;
PFP 15 µL/min, lipid 60 µL/min; and PFP 13.9 µL/min, respectively.
droplets would experience a standardized reaction to the US pressure.
Precision Size Control
The flow rates were varied over five sets of conditions for the duration of the ex-
periment to alter the droplet diameter. Results illustrated that by varying flw rates,
the PFP population diameters could be carefully selected. In general, as the lipid flow
rate was increased, droplet size decreased (Figure 8.1). As the PFP flow rate was in-
creased, droplet size increased. Table 2 lists the flow rates, mean droplet size, standard
deviation, and polydispersity index (Xu et al., 2006).
For the populations studied, the standard deviation was largest for the smallest
droplets (SD=0.4 for the 7.4 micron population) and smallest for the largest droplets
(0.3 for the 20.4 micron population). All populations had a polydispersity index of 5.1
or less.
Production Rate
The 20-µL/min lipid and the 12.5-µL/min PFP flow rates, which resulted in 20.4 mi-
cron droplets, had a production rate of 1.85x104 droplets produced per second (slowest
production sample); whereas the 60-µL/min lipid and 13.9-µL/min PFP flows, which
produced 7.4 micron droplets, had a production rate of 1.65x105 droplets per second
(fastest production sample). Table 3 lists the production rates for the 5 samples.
Acoustic Responses
The five samples were diluted and injected into a cellulose microcapillary tube where
droplets from each population were individually subjected to US. The US data showed
that there was a distinct vaporization threshold pressure for each diameter (Figure 8.2).
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Table 8.1: Polydispersity data for the five studied droplet populations from the day the
droplets were created and at three days, one week and two weeks.
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Figure 8.2: Average pressure of vaporization vs. average droplet diameter. Error bars
indicate standard deviations in pressure and diameter. The trendline is logarithmic.
The data trend suggests a logarithmic relationship (P = -1.80ln(D) + 7.72, R² = 0.97),
as predicted by the Antoine equation.
Long-tem stability
Populations maintained a fairly low polydispersity over a two week time period (Ta-
ble 2), and overall, the mean diameters of the populations drifted less than 4.6% (Figure
8.3). The 16.2- and 10.3-µmmean diameter populations each maintained the same poly-
dispersity, and the 20.4-, 12.6- and 7.4-µm mean diameter populations changed by a
factor of 1.8, 1.3, and 1.9, respectively.
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Figure 8.3: Microscopy images of droplets one week apart illustrating size stability.
(a–e) One week after production— populations of mean diameter of (a) 20.4±0.3 µm,
(b) 16.2±0.5 µm, (c) 12.6±0.5 µm, (d) 10.3±0.4 µm and (e) 7.4±0.4 µm. (f–j) Two
weeks after production—populations corresponding to (a–e), respectively, with mean
diameters of (f) 20.4±0.5 µm, (g) 15.5±0.5 µm, (h) 12.2±0.4 µm, (i) 10.8±0.4 µm and
(j) 7.5±0.7 µm.
Table 8.2: Production rates for droplets produced with microfluidics under varying
input flow conditions.
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8.1.5 Discussion
The method described here demonstrates the potential of production of uniform-
sized droplets for acoustic droplet vaporization using microfluidics. Data illustrate
that this technique enabled production of a population of droplets where each droplet
responded similarly to the same acoustic parameters because of uniform size. One ad-
vantage of utilizing such uniform droplets would include the ability to use the lowest
acoustic pressure possible for vaporization (because all droplets would respond sim-
ilarly), thereby achieving the highest vaporization efficiency for the lowest acoustic
pressure. Keeping the acoustic pressure as low as required would conform to the “As
Low As Reasonably Achievable (ALARA) Principle” for clinical ultrasonics. Other po-
tential advantages of uniform sized ADV agent production, although not demonstrated
here, would be the ability to tailor droplet sizes for specific vessel occlusion, or to enable
precision drug-loading for therapeutic-carrying ADV agents.
Microfluidic techniques have previously demonstrated unique utility in the con-
trolled fabrication of droplets and microbubbles. The biggest limitation to this method
to date is that the production rate is substantially slower than other droplet and mi-
crobubble production methods. Even for the fastest production method here, it would
require nearly 3 h to achieve 1x109 droplets (a similar order of magnitude to the concen-
tration of microbubble contrast agents prepared by a mechanical agitation method).
However, in the future microfluidic techniques may be scaled up to achieve higher
throughput, although the need to maintain identical dimensions and flow rates to each
orifice in order to preserve size uniformity presents a challenge. It should also be noted
that although the smallest droplets described here were approximately 7 microns, which
is likely too large for in vivo application, this size was limited only by our particular
system, and is not a fundamental limit of microfluidic droplet production. It is very rea-
sonable to anticipate that by optimizing the channel dimensions, component flow rates,
and the lipid/perfluorocarbon ratios, that droplets much smaller than 7 microns can
be prepared. Prior studies have illustrated microfluidic production of liquid droplets as
small as 100 nanometers (Tan and Lee, 2005).
8.1.6 Conclusion
A microfluidic device can produce monodisperse PFP/lipid droplets using flow fo-
cusing technology. Monodispersed PFP/lipid droplets that were subjected to US pres-
sure waves showed a uniform ADV response. The relationship formed by droplet diam-
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eter and ADV threshold agreed with the expected negative logarithmic response based
on the size of the droplets. Droplet populations produced with microfluidics were stable
within the two-week time period studied.
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8.2.1 Abstract
In this study we report on a microfluidic device and droplet formation regime ca-
pable of generating clinical-scale quantities of droplet emulsions suitable in size and
functionality for in vivo therapeutics. By increasing the capillary number—based on
the flow rate of the continuous outer phase—in our flow-focusing device, we examine
three modes of droplet breakup: geometry-controlled, dripping, and jetting. Operation
of our device in the dripping regime results in the generation of highly monodisperse
liquid perfluoropentane droplets in the appropriate 3–6 µm range at rates exceeding 105
droplets per second. Based on experimental results relating droplet diameter and the
ratio of the continuous and dispersed phase flow rates, we derive a power series equa-
tion, valid in the dripping regime, to predict droplet size, Dd ∼= 27(QC/QD)−5/12. The
volatile droplets in this study are stable for weeks at room temperature yet undergo
rapid liquid-to-gas phase transition, and volume expansion, above a uniform thermal
activation threshold. The opportunity exists to potentiate locoregional cancer therapies
such as thermal ablation and percutaneous ethanol injection using thermal or acoustic
vaporization of these monodisperse phase-change droplets to intentionally occlude the
vessels of a cancer.
2 c○ The Royal Society of Chemistry. Reprinted, with permission, from D. Bardin, T. D. Martz,
P. S. Sheeran et al., “High-speed, clinical-scale microfluidic generation of stable phase-change droplets
for gas embolotherapy,” Lab Chip, 2011.
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8.2.2 Introduction
Embolization has emerged as an accepted modality for the treatment of various
cancers, including hepatocellular carcinomas, hepatic metastases, and renal cell carci-
nomas.(Goode and Matson, 2004) The intentional occlusion of a vessel, embolization
enables the reduction of blood flow into or out of that vessel, and has typically been
used in cancer therapies to produce local ischemia resulting in tumor necrosis. Estab-
lished methods of embolization include the placement of a metal coil or soluble gelatin
sponge within the target blood vessel, or the injection of chemical or particulate agents
such as ethanol or polyvinyl alcohol particles to reduce blood flow at the site of injec-
tion or immediately downstream.(Goode and Matson, 2004; Kalman and Varenhorst,
1999)
Recently the field of medical ultrasound has shown much interest in gas embolother-
apy, in which acoustic or thermal energy induces a droplet emulsion with a volatile liquid
core to undergo a liquid-to-gas phase transition, and volume expansion, to strategi-
cally form gas emboli in vivo, as shown in Fig. 8.4. Acoustic droplet vaporization
(ADV) specifically refers to the use of focused ultrasound to induce such a transition,
in which the applied acoustic pressure supplies the necessary energy to induce super-
heated droplet emulsions to vaporize into microbubbles. The phase-change typically
results in microbubbles five to six times larger in diameter than the original droplets,
enabling these gas bubbles to occlude vessels of sufficiently small diameters, such as
capillaries and some arterioles.(Apfel, 1998; Kripfgans et al., 2000)
Studies thus far have investigated the usefulness of ADV agents to enhance con-
trast in ultrasound imaging,(Kripfgans et al., 2002) to deliver therapeutics,(Rapoport
et al., 2010; Fabiilli et al., 2010a; Fabiilli et al., 2010b) for enhanced thermal delivery
alongside highintensity focused ultrasound (HIFU),(Zhang and Porter, 2010) and for
occlusion in animal models.(Zhang et al., 2010) The choice of liquid core consists of a
number of perfluorocarbons, including perfluoropentane,(Kripfgans et al., 2000; Fabi-
illi et al., 2010b; Fabiilli et al., 2010a; Zhang et al., 2010; Kripfgans et al., 2004; Lo
et al., 2007; Rapoport et al., 2009b; Giesecke and Hynynen, 2003; Schad and Hynynen,
2010) perfluorohexane, (Fabiilli et al., 2010b; Giesecke and Hynynen, 2003) perfluorooc-
tane,(Fabiilli et al., 2009) and perfluorobutane.(Sheeran et al., 2011a) Encapsulation
of the liquid core inside a lipid, albumin or polymer shell reduces coalescence among
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Figure 8.4: Schematic of the liquid-to-gas phase transition of a phase-change droplet.
When presented with acoustic or thermal stimuli of a threshold amount, the volatile
liquid core of the droplet rapidly vaporizes within the lipid shell. Expansion to a gas
bubble enables the intentional occlusion of a target vessel in vivo. Other possible stimuli
include light and mechanical pressure.
the droplet population and increases the Laplace pressure sufficiently to enable these
volatile emulsions to remain as superheated droplets at body temperature.(Kripfgans
et al., 2000; Giesecke and Hynynen, 2003)
Current methods to generate these phase-change droplets— which include soni-
cation and high-speed mechanical agitation— typically result in a polydisperse size
distribution(Rapoport et al., 2010; Fabiilli et al., 2010a) and a nonuniform acoustic
activation threshold, as well as droplets either too large for passage through the lung
capillaries (>6 µm) or too small to occlude the desired vessel (<1 µm).(Kripfgans et al.,
2000; Zhang et al., 2010) Thus required are secondary methods of size selection such as
filtering(Kripfgans et al., 2002; Lo et al., 2006) or microfluidic sorting(Huh et al., 2007)
to control the sizes of these distributions. The Antoine equation predicts a negative
logarithmic relationship between vaporization energy and droplet diameter,(Rapoport
et al., 2009b) meaning that small droplets require more energy to vaporize than larger
droplets due to increased Laplace pressure. Hence, narrowing the droplet size distribu-
tion such that it is highly monodisperse should result in a uniform response to focused
acoustic pressure. As well, a monodisperse population of ADV agents may better target
a specific vessel diameter to improve occlusion efficiency and efficacy, and would signif-
icantly reduce unwanted bioeffects seen in vivo, including delayed febrile-like reactions
and respiratory distress.(Zhang et al., 2010; Kripfgans et al., 2000)
Droplet-based microfluidic systems have shown to be effective technologies to pro-
duce droplets(Tan et al., 2004; Nisisako et al., 2002) and microbubbles(Hettiarachchi
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et al., 2007b; Talu et al., 2007; Talu et al., 2008) in the micrometre diameter range with
high uniformity. Yet despite the attractiveness of precision control over size, shape,
and composition, these systems have traditionally been viewed as unviable as bulk
manufacturing processes owing to relatively low generation rates. At present, report-
ing of clinical-scale generation of droplet or microbubble emulsions has been limited,
and virtually absent for emulsions truly useful for in vivo intravenous or intra-arterial
therapeutics. Most recently Castro-Hernandez et al.(Castro-Hernandez et al., 2011) de-
scribed a new regime for microbubble generation dependent on the formation of a strong
pressure gradient at the bubbleproducing region. Approximately 5 µm in diameter gas-
in-water bubbles were successfully generated at the tip of a long gas ligament with rates
exceeding 105 Hz from a single channel, though bubbles were unstable due to the lack
of significant surfactant or lipid shells. Far less impressive per-channel frequencies have
been observed in liquid–liquid droplet generation systems. Nisisako and Torii(Nisisako
and Torii, 2008) achieved a throughput of 320 mL h−1 in generating approximately 100
µm droplets using a multilayer device with 256 droplet formation units and a breakup
rate of 1.4x103 droplets per second per cross-junction. Kobayashi et al.(Kobayashi
et al., 2007) reported the formulation of oil-in-water emulsions at cumulative rates up
to 2.2x104 Hz using a total of 1500 submicron-channels on single-crystal silicon plates,
although the emulsions were only moderately monodisperse with a minimum coeffi-
cient of variation (CV) of 9%. In fact, frequency distributions for various liquid–liquid
droplet generation systems, whether water in oil or oil in water, rarely exceed several
thousand droplets per second from a single channel in forming droplets seldom smaller
than 10 µm in diameter.(Teh et al., 2008) From a healthcare perspective, one could
comment that there is no practical use for these aforementioned emulsions due to ei-
ther insufficient quantity or inappropriate characteristics of the emulsion. Thus, a need
in microfluidics still exists for systems capable of generating clinical-scale amounts of
droplet or microbubble emulsions with suitable size and functionality for therapeutics.
To overcome the limitations of past droplet generation systems, we considered the
basic mechanisms of droplet generation with the intent to find a possible route to pro-
duce, in mass, micrometre-scale droplets with engineered biology. Recent publications
on the physics of fluids have reported the observation of a number of distinct droplet
formation modes in flowfocusing microfluidic devices.(Anna and Mayer, 2006; Cubaud
and Mason, 2008) Under controlled experimental conditions, such a device transitions
from geometry-controlled mode to dripping to jetting, affecting the size and genera-
tion frequency by up to an order of magnitude. In particular, Anna and Mayer(Anna
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Figure 8.5: Geometry of the device for the generation of liquid perfluoropentane phase-
change droplets. (a) Schematic view of the microfluidic flow-focusing device. All chan-
nels are rectangular with a height of 25 µm. (b) Image of the flow-focusing region. Lipid
solution and liquid perfluoropentane distribution channels measure 38 µm in width and
direct flows to a 7 µm orifice. Expanding nozzle geometry precedes a postorifice channel
30 µm in width. (c) Overhead view of the assembled PDMS device relative to a dime.
and Mayer, 2006) allude to the dripping mode of droplet breakup as a method to
yield droplets smaller than the minimum device feature size with a shorter primary
breakup period than other modes, as yet demonstrated in the literature with a health-
care intent. We thus set out to use the dripping regime to meet our objective of the
clinic-ready manufacture of liquid perfluoropentane droplets as phase-change agents for
cancer treatment.
In this work we present a microfluidic device, operated in the dripping regime, for
the super high-speed generation (>105 Hz) of monodisperse liquid perfluoropentane
droplets in the desired size range for gas embolotherapy. Resulting droplet popula-
tions exhibit polydispersity index values of <5%, are stable at room temperature for
several weeks, and are thermally vaporized at 88°C in a water bath. These liquid
perfluoropentane droplets thus exhibit phase-change and are ideal for targeted vessel
occlusion alongside such cancer therapies as HIFU, radiofrequency ablation (RFA),
laser ablation (LA), laser-induced thermotherapy (LITT), and chemotherapy. Our mi-
crofluidic device, shown in Fig. 8.5, features a hydrodynamic flow-focusing region and
expanding nozzle geometry to generate monodisperse liquid perfluoropentane droplets
encapsulated in a lipid shell.
8.2.3 Materials and methods
Device design
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The microfluidic device, made of polydimethylsiloxane (PDMS) on a glass substrate,
consists of fixed geometric channels designed to direct liquid perfluoropentane and a
lipid solution to an orifice 7 µm in width. Filter channels of the same dimension
immediately follow both inlets to prevent clogging at the orifice. Serpentine distribution
channels increase the resistance between inlets and the orifice chamber, minimizing the
susceptibility of droplet generation to disruptions in the fluid flows and increasing the
pressure drop along the longitudinal axis of the device. Liquid perfluoropentane and
lipid distribution channels each measure 38 µm in width. The post-orifice channel
measures 30 µm in width.
Device operation: droplet formation regimes
The principle behind a microfluidic flow-focusing system is to force a central stream
of a dispersed phase and two side sheath flows of a continuous phase through a small
orifice, causing a focusing effect and a breaking of the thread at the orifice into uniform
emulsions.(Tan et al., 2006)
Most traditional flow-focusing devices have been operated in the geometry-controlled
mode, termed for the large dependence of droplet size on the smallest feature size in
the device—the orifice. In this mode droplets break off from the dispersed phase fin-
ger following a protrude-and-retract mechanism.(Garstecki et al., 2005) Droplets in the
geometry-controlled mode are highly monodisperse but limited in minimum size by the
width of the orifice.
An increase in the capillary number Ca = ηV/γEQ, where η is the viscosity, V
is the superficial velocity of the continuous outer phase, and γEQ is the equilibrium
surface tension between the two fluid phases, leads to droplet generation in the dripping
regime.(Anna and Mayer, 2006) This regime produces monodisperse droplets smaller
than the size of the orifice due to narrowing of the dispersed phase finger. The dripping
mode is characterized by a dispersed phase tip that does not retract but rather remains
at a fixed location in the orifice, generating a stream of droplets off the tip due to
Rayleigh capillary instability.
A further increase in the capillary number leads to droplet generation in the jetting
mode, wherein the dispersed phase finger extends far into the post-orifice channel.
Droplets, which break off the tip of the dispersed phase finger due again to Rayleigh
capillary instability, tend to be as large as or larger than the orifice width in the jetting
mode and may be polydisperse.(Anna and Mayer, 2006)
By adjusting the flow parameters and continuous phase viscosity, we thus aimed to
operate our flow-focusing microfluidic device in the dripping regime to attain droplets
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of the desired size for gas embolotherapy (1–6 µm in diameter).
Microfabrication and assembly
Standard soft lithography techniques(Xia and Whitesides, 1998) were used to fab-
ricate the microfluidic devices. Devices were designed as vector-based fluidic channel
geometries in Illustrator (Adobe) and printed at 20 000 DPI by CAD/Art Services. In
a class 10,000 clean room, a 25 µm layer of a UV-curable epoxy (SU8-25, MicroChem)
was spun onto a 3 inch silicon wafer and exposed to UV-light through the photomask
and developed.
Next, PDMS (Sylgard 184, Dow Corning), consisting of 10 : 1 prepolymer to curing
agent, was poured over the patterned silicon wafer in a Petri dish to mold a silicon
elastomer replica. The Petri dish was then vacuumed for at least half an hour to degas
the PDMS and left overnight in a 70°C temperaturecontrolled dry oven to cure fully.
The device was peeled from the hard master in a laminar flow chamber and inlets and
outlet were punched using a blunt 18G needle. A soda lime glass slide was cleaned
with isopropyl alcohol prior to use as the substrate. The cured PDMS device and clean
glass slide were bonded after 150 seconds in air plasma at 250 milliTorr. DI water was
added to the outlet after plasma preparation and allowed to wick in order to maintain
the hydrophilicity of the channels.
Chemicals
A lipid shell was chosen over an albumin shell, as albumin shells have shown an
increased tendency to become lodged in the pulmonary capillaries.(Zhang et al., 2010)
Adapted from Hettiarachchi et al.,(Hettiarachchi et al., 2009) the lipid flow stream con-
sists of an aqueous glycerol mixture with the stabilizing lipids DSPC (1,2-distearoyl-
sn-glycero-2-phosphocholine, Avanti Polar Lipids) and DSPE-PEG2000 (1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], Avanti Po-
lar Lipids). Briefly, 5 mg DSPC and 1.96 mg DSPE-PEG2000 were combined in a glass
vial and dissolved in chloroform (CHCl3, Sigma) to form a homogeneous mixture. The
solvent was evaporated with a nitrogen stream and the vial was placed in a vacuum
chamber for half an hour to ensure a complete dry. Five microlitres of ultra-pure water
was added to the dry lipid mixture and sonicated at room temperature for 20 min-
utes. The solution was combined with an additional 1 mL of ultra-pure water, 4 mL of
glycerol (Sigma), and 1 mL of nonionic surfactant (Pluronic F-68, Sigma), sonicated at
room temperature for 10 minutes, and stirred overnight to ensure air saturation. The
lipid solution was sonicated again for 15 minutes immediately prior to use to minimize
unwanted liposome formation.
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Perfluoropentane (dodecafluoropentane, C5F12, FluoroMed) was chosen as the liquid
perfluorocarbon. Typical physical characteristics of perfluoropentane include a boiling
point of 29°C—below the body temperature, 37°C—and a molecular weight of 288 g
gmole−1.
Imaging and characterization
The microfluidic device was mounted on an inverted microscope (IX71, Olympus)
and external fluidic connections were made. The continuous lipid phase was supplied
to the device via flexible tubing (Tygon, Sigma) and pumped at a volumetric flow rate
of QL using a digitally controlled syringe pump (Pico Plus, Harvard Apparatus). The
dispersed liquid perfluoropentane phase was delivered into the inlet of the microfluidic
chamber using a homemade pressure pumping system controlled by an analytic regu-
lator. Pressure pumping of the dispersed phase effectively minimized fluctuations in
the liquid perfluoropentane flow and eliminated the buildup of pressure, characteristic
of constant flow rate mechanical pumping, in the inner phase channels. Also, loading
the liquid perfluoropentane was made easier by the homemade pressure pump as the
low kinematic viscosity of this perfluorocarbon at room temperature (0.4 cSt) tends
to complicate the loading of the syringe for mechanical pumping. The volumetric flow
rate (µL min−1) of the dispersed liquid perfluoropentane phase was determined from
the droplet diameter D and the droplet generation frequency fd as QP = (piD3/6) fd x C,
where C represents the necessary conversion factors. The 30-PSI limit of the analytical
regulator prevented the use of pressure pumping for the continuous lipid phase.
A high-speed camera (V310 Phantom, Vision Research, New Jersey) was used to
record videos of the droplet generation. The image analysis program ImageJ (NIH) was
used for data processing and measurements. Production rates (droplets per second)
were calculated from the videos by counting the number of droplets per 500 frames
and multiplying by the frame rate. Droplet diameters were back calculated from area
measurements of at least 50 droplets taken optically from recorded images using ImageJ.
The polydispersity index σv = δ/D x 100% for each flow condition was calculated from
the average droplet diameter D and standard deviation δ.
Droplet stability
Droplets were collected in the outlet well of the microfluidic device and transferred
to a sealed 7 mL glass vial. In contrast to previous reports, which stored droplets at
4–5°C,(Zhang et al., 2010; Schad and Hynynen, 2010) droplets in this study were stored
at room temperature to assess the viability of the droplets in an on-the-shelf setting.
At Days 0 and 14, 300 µL aliquots of the droplet solution were pipetted onto glass
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slides for stability studies. ImageJ was used to analyze at least 1000 droplets, imaged
in population at 40x magnification, to establish average diameter and monodispersity
over the two-week period.
Vaporization of droplets in a water bath
To determine the vaporization temperature of the perfluoropentane droplets, 300
µL aliquots of the droplet solution were added to 2 mL of dilute lipid solution in a 7
mL vented glass vial. The elevated density of liquid perfluoropentane (1.66 g mL−1)
relative to the solution meant that the droplets rested at the base of the vial. The vial
was suspended in a stirred water bath and the bath temperature was gradually raised
until we observed gas bubble formation and thus phase transition. The experiment
was conducted twice again with pure liquid perfluoropentane and pure lipid solution as
controls against unintended microbubble formation.
8.2.4 Results and discussion
Design optimization
Channel geometry, in addition to the compositions of fluid layers and the presence of
surfactants, affects the stability of droplets post-production in the microfluidic device.
Geometric optimization of the flow-focusing region enabled droplets to be produced in
a single file, even at rates exceeding 105 Hz. To increase the distance between generated
droplets at higher lipid and liquid perfluoropentane flow rates, the expanding nozzle and
post-orifice channels were narrowed to widths of 70 µm and 30 µm. This narrowing
minimized contact inhibitions in the highflow velocity environment of the expansion
chamber, where shell resistances are low, preventing droplet fusion before collection in
the outlet well.
Droplet formation regimes
By adjusting the flow parameters in our flow-focusing device, we observed each of
the three distinct droplet formation regimes detailed. At low continuous phase flow
rates QL, and correspondingly low dispersed phase pressures PP , our device produced
droplets in the geometry-controlled mode. As shown in Fig. 8.6a—comprising a series
of overlaid images, successive in time—the dispersed phase finger, initially upstream of
the orifice in this mode, protrudes beyond the constriction of the orifice and experiences
a pinching from the sidewalls, causing droplets to shear off. This protrude-and-retract
mechanism limits the droplet diameter to the width of the orifice. Droplets generated
in the geometry-controlled mode ranged in diameter from 7.9±0.1 µm at 2.44x104 Hz
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to 10.8±0.2 µm at 3.28x104 Hz.
Increasing the continuous phase flow (and, correspondingly, the capillary number)
causes an abrupt transition to the dripping regime of droplet formation, characterized
by a dispersed phase finger that narrows to a fine tip and remains in the orifice (Fig.
8.6b). Droplets, which break off the tip at high frequency due to ‘‘steady’’ Rayleigh
capillary instability, vary in size according to the width of the dispersed phase finger
rather than that of the orifice. Diameters of droplets generated in the dripping regime
ranged from 3.6±0.2 µm at 1.36x105 Hz to 10.8±0.1 µm at 5.00x104 Hz.
High continuous phase flows paired with correspondingly high dispersed phase pres-
sures transitioned droplet formation into the jetting mode. Fig. 8.6c overlays a series
of images, successive in time, to demonstrate the break off of droplets in this mode
due to ‘‘dynamic’’ Rayleigh capillary instability; relative to the dripping regime, the
dispersed phase tip extends far beyond the orifice and fluctuates in both length and
width. Droplets at the transition to the jetting regime ranged in diameter from 9.3±0.2
µm at 7.68x104 Hz to 13.5±0.1 µm at 3.84x104 Hz.
Generation of liquid perfluoropentane droplets
The flow rate parameters are determinants for stable production and precise con-
trol over the size and generation frequency of the liquid perfluoropentane droplets. In
general and regardless of the droplet formation regime, the droplet diameter D—and
consequently volume V—increases with the dispersed phase pressure PP for a fixed
continuous phase flow QL, consistent with previous studies.(Hettiarachchi et al., 2007b;
Castro-Hernandez et al., 2011; Hettiarachchi et al., 2009) Shown in Fig. 8.7a, the width
of the orifice limits the minimum droplet size in the geometry-controlled mode, while
much smaller droplets can be generated in the dripping regime. The minimum droplet
diameter tends to decrease with increasing QL, and thus increasing the capillary num-
ber, as the smallest droplets observed in this study occurred at the highest continuous
flow rates.
An interesting observation emerged when establishing trends in the droplet gener-
ation frequency fd (Fig. 8.7b). In geometrycontrolled mode, fd tends to increase with
PP for a fixed QL in order to conserve mass. Conversely, for a given QL in the drip-
ping regime, decreasing PP significantly quickens the generation frequency (increases
fd) while reducing D, hence achieving the desired super high-speed generation of func-
tional droplets suitable for therapeutic applications. Overall and as expected, fd tends
to increase with QL.
The sequence of high-speed images in Fig. 8.8 illustrates the general trends ob-
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served in the dripping regime. In particular as droplets become small, the width of the
dispersed phase finger heavily influences the diameter of the droplet after it breaks off
from the tip.
Shown in Fig. 8.9 are droplet generation frequencies obtained from high-speed
videos of production and corresponding polydispersity indexes, plotted as a function of
droplet diameter. When operated in the dripping regime our device clearly produces
liquid perfluoropentane droplets in the desired 3–6 µm range with high monodispersity
at rates equal to or exceeding 105 Hz. Whereas no general trend appears to connect
the droplet diameter and generation frequency in geometry-controlled mode, D tends
to decrease as fd quickens in the dripping regime. Simple adjustment of the flow pa-
rameters enabled the generation of droplets spanning a wide range of diameters, with
a polydispersity index less than 5% for each condition.
Determining the liquid perfluoropentane volumetric flow rate QP as detailed, we
evaluated the influence of the dimensionless flow rate ratio φ=QL/QP on the droplet
diameter and generation frequency. As shown in Fig. 8.10a, a key relationship emerges
in the dripping regime relating D and φ to predict the droplet diameter based solely
on the dimensionless flow rate ratio as: D= 27.445φ−0.414 (r2=0.99). Rounding, we
characterize our flowfocusing droplet generator, operated in the dripping regime, in
generic terms by
Dd ∼= 27(QC/QD)−5/12
where Dd represents the droplet diameter, and QC and QD represent the continuous
and dispersed phase flow rates. Note that the exponent 5/12 matches the exponent
reported by Castro- Hernandez et al.(Castro-Hernandez et al., 2011) to calculate the
gas bubble diameter based on the ratio of the flows in a high-speed regime. The
droplet generation frequency shows relatively less dependence on the dimensionless
flow rate ratio (Fig. 8.10b). In general, however, fd increases with φ in the dripping
regime and decreases with φ in geometry-controlled mode. As reported by Anna and
Mayer,(Anna and Mayer, 2006) transitions between the droplet formation regimes are
weakly dependent on φ; rather, the capillary number plays a more determining role in
controlling the mode of droplet breakup.
This study used low lipid flow rates (12–26 µL min−1) and correspondingly low
liquid perfluoropentane pressures in order to conserve fluids and better demonstrate
the viability of highspeed droplet generation as a bulk manufacturing process. By
comparison, Hettiarachchi et al.(Hettiarachchi et al., 2007b) supplied the lipid phase
at rates between 30 and 120 µL min−1. Based on the trends observed in Fig. 8.7b
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Figure 8.6: Representative images of three distinct droplet formation regimes. (a)
Geometry-controlled. A series of overlaid images, successive in time, demonstrate the
protrude-and-retract mechanism of the dispersed phase finger. (b) Dripping. Droplets
break off from the tip of the dispersed phase finger at high rates due to ‘‘steady’’
Rayleigh capillary instability. (c) Jetting. A series of overlaid images, successive in time,
demonstrate the break off of droplets due to ‘‘dynamic’’ Rayleigh capillary instability.
The image height is 25 µm.
and 8.10b, even quicker droplet generation frequencies may be attained by increasing
the continuous phase flow to further push the capillary number. As well, multiplexing
numerous flow-focusing circuits to expand the number of droplet formation units, while
maintaining device operation in the dripping regime, would scale the throughput. A
10x scale-up, for instance, would reduce the time to produce 1x109 droplets— similar
in scale to the amount of droplets formed by mechanical agitation, and well beyond
the estimated 2x107 monodisperse emulsions(Hettiarachchi et al., 2009) necessary for
therapeutics in humans—from several hours to mere minutes.
Stability
We assessed a population of droplets with a mean diameter of 4.5 µm for size stability
over a two-week time span. To our knowledge this study is the first to simulate an on-
the-shelf environment by storing phase-change droplets at room temperature. Over
two weeks the mean droplet diameter drifted less than 4%, from 4.5±0.2 µm to 4.3±0.3
µm (Fig. 8.11). It may be possible to prolong the shelf life beyond several weeks by
modifying the poloxamer or PEG group, though unnecessary in practice considering
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Figure 8.7: Diagrams of the production characteristics as determined by the flow pa-
rameters. Boxes distinguish geometry-controlled and jetting modes of droplet formation
from dripping. (a) Droplet diameter D as a function of the lipid flow QL and the liquid
perfluoropentane pressure PP . (b) Generation frequency fd as a function of QL and PP .
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Figure 8.8: Sequence of images showing the effect of liquid perfluoropentane pressure
for two lipid flows in the dripping regime. The droplet diameter decreases and the
generation frequency quickens as the dimensionless flow rate ratio φ=QL/QP increases.
(a) QL=18 µL min−1. Top to bottom: PP=17 psi, φ=55, D=4.9±0.2 µm, fd=8.82x104
Hz; PP=18 psi, φ=18, D=8.6±0.1 µm, fd=5.04x104 Hz; PP=19 psi, φ=9, D=10.0±0.2
µm, fd=4.80x104 Hz. (b) QL=22 µL min−1. Top to bottom: PP=20 psi, φ=128,
D=3.8±0.2 µm, fd=1.00x105 Hz; PP=21 psi, φ=20, D=7.9±0.1 µm, fd=7.00x104 Hz;
PP=22 psi, φ=12, D=9.8±0.2 µm, fd=6.12x104 Hz. The image height is 25 µm.
that clinical phase-change and contrast agents formed via mechanical agitation are
injected immediately into the patient.
Thermal vaporization
The relatively low boiling point of liquid perfluoropentane (29°C) suggests sponta-
neous liquid-to-gas transition at body temperature; however, consistent with previous
studies,(Kripfgans et al., 2000; Giesecke and Hynynen, 2003) encapsulation of the per-
fluorocarbon in a lipid shell increases the Laplace pressure sufficiently to stabilize the
droplets well beyond the natural boiling point of pure liquid perfluoropentane. We ob-
served rapid thermal vaporization of multiple droplet populations, collected at different
days, at 88°C in a stirred waterbath. Droplets remain in a superheated state prior to
this activation threshold.
As shown in Fig. 8.12, gas bubbles formed by vaporization expanded well beyond
the volume predicted by the ideal gas law, PV=nRT, which approximates a volume
expansion factor of 1253(Kripfgans et al., 2000). Upon activation, 4.5±0.2 µm droplets
initially converted into gas bubbles 106.7±4.6 µm in diameter, a diameter expansion
of 24x. Kripfgans et al.(Kripfgans et al., 2000) detailed this further expansion as due
to the intake of dissolved gases from the host fluid after conversion of the droplet to
the gas bubble of pure perfluoropentane, an effect we have observed experimentally
in our previous studies with perfluorocarbons.(Sheeran et al., 2011a) That the carrier
fluid was not degassed prior to heating contributed to this large initial increase in
size. Subsequent dissolution of these extra gases resulted in gas bubbles with a resting
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Figure 8.9: Plots relating the generation frequency and polydispersity index to droplet
size. The dripping regime enables droplet formation in the appropriate 3–6 µm range at
high frequency and monodispersity. (a) Generation frequency fd as a function of droplet
diameter D. (b) Polydispersity index (PDI) as a function of D. All flow conditions
generated droplets with PDI <5%.
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Figure 8.10: Diagrams of the production characteristics as determined by the ratio
of the continuous lipid flow to the dispersed liquid perfluoropentane flow, φ=QL/QP .
(a) The droplet diameter D as a function φ. For a given φ, droplet formation in
geometry-controlled mode generates droplets of a larger size than in dripping mode.
A power-series equation, valid in the dripping regime, emerges to predict droplet size
based on the dimensionless flow rate ratio as D=27.445φ0.414 (r2=0.99). (b) Generation
frequency fd as a function of φ. Increasing φ tends to slow fd in geometrycontrolled
mode and quicken fd in dripping mode.
59
Figure 8.11: Images showing stability of a droplet population over a two-week time
period. Droplets 4.5 µm in diameter drifted less than 4% in size over 14 days in a
sealed glass vial at room temperature. Thus our phase-change droplets exhibited high
stability in a true on-the-shelf setting. Scale bar represents 5 µm.
diameter of 27.4±1.2 µm, a 6x increase from the original droplet diameter, imaged
several days after vaporization (Fig. 8.12, inset).
These experiments were repeated for vials containing pure liquid perfluoropentane
and pure lipid solution. Under observation, pure liquid perfluoropentane transitioned
directly to gas perfluoropentane, thus leaving an ‘‘empty’’ vial. Pure lipid solution
boiled up to 120°C without the formation of gas bubbles.
The size stability of our droplets enabled consistent thermal activation of droplet
populations stored at room temperature over two weeks. At threshold, droplet acti-
vation occurs in a near simultaneous manner. Likewise, we demonstrate in a parallel
study that monodisperse droplets generated by our microfluidic device respond uni-
formly to acoustic pressure delivered from a 5 MHz piston transducer.(Martz et al.,
2011) This parallel study confirms our initial hypothesis that acoustic droplet vapor-
ization can be made homogeneous by the precision engineering of phase-change agents
using microfluidics.
Consistent thermal and acoustic responses make these liquid perfluoropentane droplets
ideal for targeted vessel occlusion to enhance HIFU, RFA, LA, and LITT in the treat-
ment of cancers such as hepatocellular carcinomas, hepatic metastases, and renal cell
carcinomas. The inclusion of an anti-cancer drug layer within the droplet may fur-
ther potentiate these treatment modalities. Our device design lends itself to the in-
clusion of such a drug layer by combining a second hydrodynamic flow-focusing re-
gion at the droplet formation unit, as done in microbubble studies by Hettiarachchi
et al.(Hettiarachchi et al., 2009) Chemoembolization—the addition of a chemother-
apeutic agent—has been used to reduce perfusion and deliver therapeutics to treat
60
Figure 8.12: Thermal vaporization of a population of liquid perfluoropentane droplets
after heating in a stirred water bath. Rapid droplet activation was observed at a water
bath temperature of 88°C. Upon vaporization, 4.5 µm droplets initially transitioned into
gas bubbles 106.7 µm in diameter. (Inset) Occlusive bubbles with a resting diameter
of 27.4 µm resulted following dissolution of extra gases.
renal cell carcinoma alongside RFA(Arima et al., 2007) and hepatocellular carcinoma
alongside RFA(Yamakado et al., 2009) and HIFU.(Wu et al., 2005) Besides forming
polydisperse size distributions, conventional production techniques result in inconsis-
tent drug dosages. Manufacturing utilizing microfluidics enables the accurate control
of therapeutic payloads, and thus may improve localized drug delivery as well as ther-
mal and acoustic responses. Further, adaptation of our microfluidic device to produce
monodisperse double emulsions may enable the encapsulation of hydrophilic drugs such
as thrombin(Fabiilli et al., 2010b) to extend the duration of occlusions generated by
phase-change agents.
8.2.5 Conclusion
With microfluidics we can generate highly monodisperse phase-change droplets in
the size range suitable for gas embolotherapy as a cancer treatment. By adjusting the
flow rate of the contin- uous outer phase, we varied the capillary number and observed
three distinct droplet formation regimes: traditional geometry- controlled mode, char-
acterized by a protrude-and-retract mechanism of droplet break off; dripping, character-
ized by ‘‘steady’’ Rayleigh capillary instability; and jetting, characterized by ‘‘dynamic’’
Rayleigh capillary instability. Geometric optimization of the flow-focusing region and
operation of the device in the dripping regime enabled the single-file generation of
droplets at rates exceeding 105 Hz. To our knowledge this study is the first to report
on the generation of clinical-scale quantities of droplet emulsions truly suitable for in
vivo intravenous therapeutics.
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For our flow-focusing device operated in the dripping regime, we can predict droplet
diameter Dd based on the dimensionless ratio of the flow rates of the continuous outer
phase QC and the dispersed inner phase QD. In simplified terms, we characterize our
device in the dripping regime by Dd∼= 27(QC/QD)−5/12.
Droplet populations generated by our microfluidic device are monodisperse, stable
at room temperature, and transition uniformly to gas bubbles when presented with
thermal and acoustic stimuli. Looking ahead, we aim to build a drug layer into our liq-
uid perfluoropentane droplets to generate, using super high-speed microfluidics, phase-
change droplets for gas chemoembolotherapy. Simultaneous delivery of a chemother-
apeutic agent should elevate local concentrations of the drug with little escape to the
systemic circulation due to vessel occlusion. Combining gas chemoembolotherapy with
locoregional therapies such as thermal ablation and percutaneous ethanol injection
presents a nice prospect to enhance heat and alcohol trapping and more effectively
treat cancers.
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8.3.1 Introduction, Results, Discussion & Conclusion
Liquid perfluorocarbon droplets have emerged in medical acoustics as acoustically
active particles for applications in embolization, contrast imaging, and targeted thera-
peutics. Acoustic droplet vaporization (ADV) occurs when the inner core of a perflu-
orocarbon droplet phase-shifts from the liquid state to the gas state as a result of an
applied ultrasound pressure. Whereas the initial liquid droplet benefits from increased
stability and small size, the resultant echogenic bubble can provide contrast to enhance
ultrasound(Kripfgans et al., 2002) or can potentiate the delivery of therapeutics.(O’Neill
and Rapoport, ) The most common liquids of the droplet core, compounds in the per-
fluorocarbon family are non-toxic in small doses and inert, and, due to high molecular
weights, are moderately stable in circulation.(Mattrey, 1994) While most ADV inves-
tigations have focused on droplets in the micron range for intravascular procedures,
the field of medical ultrasound has shown recent interest in sub-micron liquid perfluo-
rocarbon droplets for extravascular applications. Capitalizing on the characteristically
‘leaky’ vasculature of many solid tumors, sub-micron droplets may extravasate into the
tumor interstitium through inter-endothelial gaps and accumulate(Campbell, 2006), or
may be able to traverse the lymphatic system. Prior studies have shown sub-micron
ADV agents to be useful in drug delivery(Rapoport et al., 2009b), enhanced thermal
ablation(Zhang and Porter, 2010; Kawabata et al., 2005), and diagnostic imaging and
3Submitted to Small. Permission granted from T. D. Martz, D Bardin, P. S. Sheeran et al.
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tissue characterization.(Martz et al., 2011; Kawabata et al., 2005; Sheeran, 2011; Asami
et al., 2010) Rapoport et al.(Rapoport et al., 2009b) in particular demonstrated, in vivo,
that paclitaxel-loaded droplets can be released with high spatial specificity, resulting
in tumor regression. One main limitation of current methods is the use of processing
techniques such as emulsification(Kawabata et al., 2005) and sonication(Mohan and
Rapoport, 2010) to generate these nanodroplets, which result in polydisperse popula-
tions and significant variation in the reported activation threshold due to the strong
correlation between vaporization energy and perfluorocarbon droplet size.(Martz et al.,
2011; Sheeran et al., 2011b) Narrowing the size distribution would likely improve the
biodistribution of sub-micron ADV agents, as well. Significant clinical motivation thus
exists for a precise method to generate perfluorocarbon nanodroplets for use in ex-
travascular tumor therapies.
Previously our group assessed the feasibility of microfluidic generation of ADV
agents in the micron range to achieve precision control of droplet size and uniform
activation. (Martz et al., 2011; Bardin et al., 2011) In this manuscript, we present a
novel microfluidic system to generate engineered populations of sub-micron liquid per-
fluoropentane droplets for contrast-enhanced ultrasound imaging of the tumor intersti-
tium. Compared with previous microfluidic systems to generate nanodroplets which
relied on satellite droplet sorting(Tan and Lee, 2005) to produce droplets sizes as small
as 100 nm, our system uses tip-streaming, made consistent with a pressure-controlled
reagent delivery system and enhanced with the addition of a surfactant(Ward et al.,
2010) to the continuous phase, to generate primary droplets of lipid-encapsulated per-
fluorocarbons as small as 360 nm, despite an orifice width of over an order of magnitude
larger. Relative to satellite droplet sorting, advanced tip-streaming, as we demonstrate
(Figure 8.13), allows for efficiency in generating droplets in the sub-micron range, with-
out filtration or dynamic in-device separation.
By precisely varying the pressures and, consequently, the flow rates of the continuous
and dispersed phases, we were able to produce narrowly dispersed lipid-encapsulated
nano- and microdroplets ranging from 360 nanometers to 11 microns with the same
microfluidic device (Table 8.3). Droplets larger than 1 micron were quantified with high-
speed light microscopy as they exited the orifice. Production rates of 3.6±0.2, 6.8±0.2,
and 11.8±0.3 micron droplets were 8.7, 4.0, and 3.2 x104 droplets/second, respectively.
Smaller droplets could not be resolved with traditional light microscopy, and hence
were collected and then assessed by dynamic light scattering with a Malvern Nanosizer
(Figure 8.14) after production and thus production rate data was not obtained. TEM
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of a number of the samples verified results of the Malvern Nanosizer (Figure 8.15).
In order to confirm the resulting samples were acoustically vaporizable, droplets
were sonicated with 100 cycle pulses of varying amplitude at 3.2 MHz. As described by
Sheeran et al (2011)(Sheeran et al., 2011a), the pressure required to vaporize droplets
increases as droplet size decreases. In this study, a peak rarefactional pressure of ap-
proximately -3.15 MPa was sufficient to vaporize the majority of droplets in focus when
the droplet size was greater than approximately 7 µm in diameter. As expected, smaller
samples required substantially more pressure to vaporize. Droplets near 0.9 µm in di-
ameter required approximately 4 MPa to vaporize, while smaller droplets could not be
vaporized due to the maximum output limit of our ultrasound system (4.3 MPa peak
rarefactional pressure). Activation thresholds established from these studies is in agree-
ment with vaporization thresholds previously identified for individual perfluoropentane
droplets.(Martz et al., 2011) That bulk droplet samples can be activated at pressures
similar to the thresholds for individual droplets confirms one of the chief benefits of
ADV droplet production through microfluidics – uniform activation.
Our results demonstrate that sub-micron (and micron) droplets for acoustic droplet
vaporization applications can be effectively generated using droplet-based microfluidics.
The pressure-controlled reagent delivery system crucially enabled the quick and pre-
cise tuning of the continuous and dispersed phases to maintain constant rates of flow
and a consistent tip-streaming. By contrast, in our prior studies utilizing mechanical
pumping, we were unable to maintain the tip-streaming of sub-micron droplets for suf-
ficient time to collect samples. To our knowledge, this study is the one of the first
examples of sub-micron production of primary encapsulated liquid droplets from a mi-
crofluidic device. The ability to achieve sub-micron droplet production, as well as the
ability to produce droplet populations of uniform size, will have a significant impact in
burgeoning medical applications requiring acoustically active nano- and microdroplets.
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Table 8.3: Average diameter, standard deviation, and production rate for perfluorocar-
bon droplets produced with microfluidic flow focusing.
Figure 8.13: “Nano tipstreaming” of submicron droplets in a microfluidic device. Indi-
vidual nanodroplets cannot be resolved by optical microscopy.
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Figure 8.14: Particle size distribution, as reported by the Malvern Nanosizer, for 850
± 150 nm population.
Figure 8.15: Transmission electron microscopy example of negative-stained perfluoro-
carbon droplets. Size measurement of 30 droplets indicated a distribution of 312 ± 49
nm.
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8.3.2 Experimental Section
Reagent Preparation: The continuous phase lipid solution was prepared using a 9:1
molar ratio of 1,2-distearoyl-sn-glycero-3-phosphocoline (DSPC) (Avanti Polar Lipids,
Alabaster, AL) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy-(polyethylene
glycol)-5000] (DSPE-PEG5000) (Avanti Polar Lipids, Alabaster, AL) in saline. Lipid
solution was combined with glycerol (Fisher Scientific, Pittsburgh, PA) and Pluronic
F-68 (Sigma Aldrich Corporation , St. Louis, MO) in a 1:1:1 mL volumetric ratio. Liq-
uid perfluoropentane (FluoroMed, Round Rock, Texas) was utilized as the dispersed
phase.
Microfluidic Device Fabrication: The process for developing the microfluidic wafer
has been previously described by Hettiarachchi el al. (2009).(Hettiarachchi et al., 2009)
Briefly, microfluidic channels were designed using Illustrator (Adobe, San Jose, CA)
and printed at 20,000 dpi by CAD/Art Services (Brandon, OR). In a class 10,000
clean room, a silicon wafer spin-coated with a UV-curable epoxy (SU-8-25, MicroChem,
Newton, MA) and exposed to UV light to develop the channels as a negative mold. Bulk
polydimethylsiloxane (PDMS) (Dow Corning, Midland, MI) and a curing agent were
cast over the wafer at a 10:1 ratio, and the mold was cured at 60°C for at least eight
hours. Microfluidic chips were separated from the wafer and cleaned along with the
glass slides (2947-75X25, Corning, Corning, NY) in a plasma cleaner (Harrick Plasma,
Ithaca, NY). The device components were exposed to a plasma field under a controlled
pressure of 500 millitorr for three minutes. Upon removal, the microfluidic channels
and glass slide were joined, creating a sealed microfluidic device. Then the channels
were filled with deionized water to stabilize the hydrophilic environment.
Optical Observations: The microfluidic device was secured to a moving stand on an
inverted microscope (Olympus 1X71 microscope, Center Valley, PA) with a 50X NA =
1.0 objective. A high-speed camera (FastcamAPX-RS, Photron, Inc., San Diego, CA)
was used to capture images and videos of the device output.
Pressure Control Flow System: The reagent pump system was established in a sim-
ilar manner to Korczyk.(Korczyk et al., 2010) The pressure to control the flow system
was supplied by a compressed nitrogen tank with precision regulators for both the con-
tinuous and discontinuous flows. Each reagent vial had two holes in the septum, which
were fed by Tygon S-54-HL tubing (Saint-Gobain Performance Plastics, Akron, OH).
One tube was placed in the headspace that was connected to the pressure regulation
system. The second tube was immersed in the reagent, which transferred the reagent
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to the microfluidic device. The system was allowed to stabilize for one minute after
pressure changes before sample collection began.
Optical Imaging and Sizing: Dimensions of the final microfluidic device were de-
termined using Image J (NIH, Bethesda, Maryland) and a calibrated slide reticule
(Edmund Optics, Barrington NJ). The orifice was 12 µm, the PFP channel was 46 µm,
the lipid solution channel was 45 µm, and the filter spacing was 23 µm.
For micron sized droplets, diameter was determined optically as described for mea-
surements of the microfluidic chip. Sub-micron droplets could not be resolved optically,
and were instead collected in a pipette tip for light scattering or electron microscopy
analysis.
Dynamic Light Scattering Sizing: A Malvern Nano ZS (Malvern Instruments Ltd.,
Malvern, Worcestershire, U.K.) was used to size droplets in the sub-micron diameter
range. Sub-micron samples were diluted with 0.5 mL of phosphate buffered saline and
placed into a cuvet for testing. Debris less than 100 nm were assumed to be lipid
micelles.
Transmission Electron Microscopy (TEM) and Sizing: To verify the presence of
perfluorocarbon droplets and corroborate Malvern sizing data, a negative staining pro-
cedure was used along with a TEM (Philips Tecnai 120kV, Amsterdam, The Nether-
lands). The negative staining first consisted of plasma treating the individual TEM
grids for 90 seconds. 10 µl of the droplet sample was transferred via pipette onto the
TEM grid and allowed to sit for 120 seconds. The TEM grid was dipped in a bath of
1% uranyl acetate for 60 seconds, and allowed to dry prior to TEM imaging.
Acoustic Droplet Vaporization: To verify that the generated droplet samples could
be vaporized, a procedure similar to that described in Sheeran et al.(Sheeran, 2011)
was utilized. In brief, a 3.2 MHz transducer with a focal length of 3.45 cm was used to
activate the droplets in a cellulose tube submerged in a water bath at 37°C. Droplets
within the optical focus were subjected to manually-triggered 100 cycle pulses with 1-2
seconds of rest between each trigger. Pressure was increased in steps of approximately
0.15 MPa until the pressure was sufficient to vaporized the majority (approximately
90% or greater) of the droplets in focus.
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